E. David Crawford, MD, and Daniel P. Petrylak, MD, discuss PARP inhibition, TALAPRO-3, HRR alterations, and genomic testing in metastatic prostate cancer.
Read More
Dr. Andrew W. Hahn reviews current treatment strategies after androgen receptor pathway inhibition and radioligand therapy, discussing sequencing challenges, molecular heterogeneity, biomarker-driven care, and emerging therapeutic approaches for advanced prostate cancer.
Read More
Dr. Hanan Goldberg reviews current evidence supporting metastasis-directed therapy for oligometastatic prostate cancer while discussing systemic therapy, PSMA PET, patient selection, and the unanswered questions that continue to shape clinical practice.
Read More
Dr. Abraham Morgentaler examines the historical origins of testosterone concerns in prostate cancer and reviews modern evidence supporting a reassessment of testosterone therapy in appropriately selected men.
Read More
Dr. E. David Crawford, Dr. Jason M. Hafron, and Dr. Michael Granieri discuss why low-dose-rate brachytherapy remains an important treatment option for localized prostate cancer, highlighting patient selection, multidisciplinary collaboration, and successful implementation within modern urology practices.
Read More